As of 2026-01-07, the EV/EBITDA ratio of Sangamo Therapeutics Inc (SGMO) is -1.11. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGMO's latest enterprise value is 119.82 mil USD. SGMO's TTM EBITDA according to its financial statements is -108.32 mil USD. Dividing these 2 quantities gives us the above SGMO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.9x - 15.6x | 15.2x |
| Forward P/E multiples | 22.0x - 53.9x | 38.0x |
| Fair Price | (6.99) - (4.93) | (8.48) |
| Upside | -1675.0% - -1211.0% | -2008.4% |
| Date | EV/EBITDA |
| 2026-01-05 | -1.09 |
| 2026-01-02 | -1.09 |
| 2025-12-31 | -1.03 |
| 2025-12-30 | -1.05 |
| 2025-12-29 | -1.00 |
| 2025-12-26 | -1.05 |
| 2025-12-24 | -1.11 |
| 2025-12-23 | -1.06 |
| 2025-12-22 | -1.16 |
| 2025-12-19 | -1.11 |
| 2025-12-18 | -1.06 |
| 2025-12-17 | -1.09 |
| 2025-12-16 | -1.10 |
| 2025-12-15 | -1.09 |
| 2025-12-12 | -1.12 |
| 2025-12-11 | -1.15 |
| 2025-12-10 | -1.23 |
| 2025-12-09 | -1.29 |
| 2025-12-08 | -1.29 |
| 2025-12-05 | -1.27 |
| 2025-12-04 | -1.37 |
| 2025-12-03 | -1.28 |
| 2025-12-02 | -1.09 |
| 2025-12-01 | -1.05 |
| 2025-11-28 | -1.16 |
| 2025-11-26 | -1.17 |
| 2025-11-25 | -1.02 |
| 2025-11-24 | -1.02 |
| 2025-11-21 | -1.04 |
| 2025-11-20 | -0.92 |
| 2025-11-19 | -0.94 |
| 2025-11-18 | -1.04 |
| 2025-11-17 | -1.00 |
| 2025-11-14 | -1.11 |
| 2025-11-13 | -1.12 |
| 2025-11-12 | -1.19 |
| 2025-11-11 | -1.29 |
| 2025-11-10 | -1.32 |
| 2025-11-07 | -1.19 |
| 2025-11-06 | -1.16 |
| 2025-11-05 | -1.44 |
| 2025-11-04 | -1.47 |
| 2025-11-03 | -1.52 |
| 2025-10-31 | -1.58 |
| 2025-10-30 | -1.50 |
| 2025-10-29 | -1.53 |
| 2025-10-28 | -1.56 |
| 2025-10-27 | -1.68 |
| 2025-10-24 | -1.69 |
| 2025-10-23 | -1.77 |